The Association of Fetal Acidemia With Adverse Neonatal Outcomes at Time of Scheduled Cesarean Delivery

Abstract

Taking these limitations into account, it could be said that effects may be more visible in a study where the timing of drug administration is better aligned with optimizing the risk-to-benefit ratio. In this line of thinking, dosage may matter more when used in the optimal timeline, or there may be difficulties generalizing to a population in this timeline.Evaluating this study in the context of current clinical practice, it appears that there is little evidence to suggest a change in the treatment regimen of betamethasone. There may be more evidence after following up with the infants examined in this study, and there are several future studies planned that will assess the two treatment regimens in more depth in the hope of illustrating more clearly the benefits and risks of antenatal betamethasone.